Increased mature (CD57+) and cytotoxic (CD16+ and CD57+) NK cells, together with IFN therapy prior to TKI cessation, have been also shown to produce better CML outcomes after treatment interruption [60]. The gene discussed is B3GAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.